Article Text

Download PDFPDF
Cannabis hyperemesis syndrome: an emerging clinical and public health challenge
    1. Pharmacy, SERGAS, Santiago de Compostela, Spain
    1. Correspondence to Dr Aron Misa Garcia; aronmisagarcia{at}gmail.com

    Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Cannabis hyperemesis syndrome (CHS) is a relatively recent clinical condition, first described in 2004. The disorder occurs in chronic cannabis users who, after prolonged cannabis use, develop cyclical episodes of vomiting, severe nausea and abdominal pain.1

    The incidence of CHS has increased with the growth of cannabis use worldwide. In the USA, recent studies indicate that up to 33% of users may be affected. In addition, one study estimated that approximately 2.39% of emergency department visits may be related to this condition. Lack of awareness among healthcare workers about this syndrome complicates its diagnosis, often leading to costly and …

    View Full Text

    Footnotes

    • Contributors AMG and SFR have made substantial contributions in each of the following aspects: the writing of the article, the revision of the content and the final approval of the version presented. Guarantor: AMG.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.